(Q38875632)

7 September 2017

1 reference

title

The mTOR signalling cascade: paving new roads to cure neurological disease (English)

1 reference

7 September 2017

Peter B Crino

1

1 reference

PubMed ID

27340022

7 September 2017

language of work or name

English

0 references

publication date

24 June 2016

1 reference

7 September 2017

Nature Reviews Neurology

1 reference

7 September 2017

12

1 reference

7 September 2017

7

1 reference

7 September 2017

379-392

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2016.81

7 September 2017

0 references

cites work

The neurology of mTOR

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR in Brain Physiology and Pathologies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR: A pathogenic signaling pathway in developmental brain malformations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR signaling in epilepsy: insights from malformations of cortical development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The structural basis for mTOR function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR signaling in growth control and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Molecular mechanisms of mTOR-mediated translational control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

IGF-1 receptor antagonism inhibits autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Regulation of mammalian autophagy in physiology and pathophysiology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Recent insights into cell death and autophagy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian Target of Rapamycin (mTOR) Tagging Promotes Dendritic Branch Variability through the Capture of Ca2+/Calmodulin-dependent Protein Kinase II α (CaMKIIα) mRNAs by the RNA-binding Protein HuD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

MEK-ERK1/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Tsc2-Rheb signaling regulates EphA-mediated axon guidance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Activity-dependent rapid local RhoA synthesis is required for hippocampal synaptic plasticity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Dendritic mRNA targeting and translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR kinase: a possible pharmacological target in the management of chronic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Neurological and neuropsychiatric aspects of tuberous sclerosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR cascade activation distinguishes tubers from focal cortical dysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Fetal brain mTOR signaling activation in tuberous sclerosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Biallelic TSC gene inactivation in tuberous sclerosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Impaired Reelin-Dab1 Signaling Contributes to Neuronal Migration Deficits of Tuberous Sclerosis Complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Role of the mTOR signaling pathway in epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Hemimegalencephaly, a paradigm for somatic postzygotic neurodevelopmental disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Inherited PTEN mutations and the prediction of phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Somatic activation of AKT3 causes hemispheric developmental brain malformations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Depdc5 knockout rat: A novel model of mTORopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Somatic mutation, genomic variation, and neurological disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Autism and fragile X syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Dysregulation of mTOR signaling in fragile X syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mutations causing syndromic autism define an axis of synaptic pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Genetics: influence of TOR kinase on lifespan in C. elegans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The role of mTOR signaling in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR Hyperactivation in down syndrome hippocampus appears early during development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Elucidating the role of DEPTOR in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

α-Synuclein Is Degraded by Both Autophagy and the Proteasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Lithium induces autophagy by inhibiting inositol monophosphatase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Huntingtin functions as a scaffold for selective macroautophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Cutting through the complexities of mTOR for the treatment of stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The rationale of targeting mammalian target of rapamycin for ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin induces of protective autophagy in vascular endothelial cells exposed to oxygen-glucose deprivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Mammalian target of rapamycin cell signaling pathway contributes to the protective effects of ischemic postconditioning against stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin treatment improves neuron viability in an in vitro model of stroke.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin is a neuroprotective treatment for traumatic brain injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Beneficial Effects of Early mTORC1 Inhibition after Traumatic Brain Injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR signaling in glioblastoma: lessons learned from bench to bedside

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

The mTOR signaling pathway as a treatment target for intracranial neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Conditional astroglial Rictor overexpression induces malignant glioma in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Differential cellular gene expression in ganglioglioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTORC1 inhibitors suppress meningioma growth in mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus alters white matter diffusion in tuberous sclerosis complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

mTOR inhibitors as a new therapeutic option for epilepsy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.81

Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.

31 March 2020

1 reference

12 December 2020

Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.

1 reference

12 December 2020

Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.

1 reference

12 December 2020

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo

1 reference

12 December 2020

Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2016.81

1 reference

PubMed ID

27340022

Dimensions Publication ID

7 September 2017

0 references

1 reference

PubMed ID

27340022